Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine multizentrische, offene klinische Phase-I-Studie zur Bewertung der Sicherheit, Verträglichkeit, des pharmakokinetischen Profils und der vorläufigen Wirksamkeit von BL-M11D1 bei Patienten mit rezidivierter/refraktärer akuter myeloischer Leukämie

21. September 2026 aktualisiert von: SystImmune Inc.

Eine multizentrische, offene klinische Phase-I-Studie zur Bewertung der Sicherheit, Verträglichkeit, des pharmakokinetischen Profils und der vorläufigen Wirksamkeit von BL-M11D1 bei Patienten mit rezidivierter/refraktärer akuter myeloischer Leukämie.

The objective of this study to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of BL-M11D1 in patients with relapsed/refractory acute myeloid leukemia.

Studienübersicht

Status

Beendet

Intervention / Behandlung

Detaillierte Beschreibung

BL-M11D1-HM-101 is a multi-center, Phase 1 study to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of BL-M11D1 in patients with relapsed/refractory acute myeloid leukemia.

This study will be conducted in two parts (dose escalation, and dose finding). Cohort A will be dosed on Days 1, 8,15 of a continuous 28-day treatment cycle. The cohort has different dose groups. Cohort B will be dosed on Days 1, 4, 7 or 8 of a continuous 28-day treatment cycle. The cohorts have different dose groups.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

52

Phase

  • Phase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • California
      • Duarte, California, Vereinigte Staaten, 91010
        • City of Hope
      • Los Angeles, California, Vereinigte Staaten, 90095
        • UCLA Ronald Reagan Medical Center
    • Colorado
      • Aurora, Colorado, Vereinigte Staaten, 80045
        • University of Colorado Anschutz Medical Campus
    • Connecticut
      • New Haven, Connecticut, Vereinigte Staaten, 06511
        • Yale Cancer Center, Smilow Cancer Hospital at Yale New Haven
    • Florida
      • Tampa, Florida, Vereinigte Staaten, 33612
        • Moffitt Cancer Center
    • Illinois
      • Chicago, Illinois, Vereinigte Staaten, 60611
        • Northwestern Memorial Hospital
    • Maryland
      • Baltimore, Maryland, Vereinigte Staaten, 21287
        • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    • Michigan
      • Grand Rapids, Michigan, Vereinigte Staaten, 49546
        • START Midwest/The Cancer and Hematology Center
    • New Jersey
      • Hackensack, New Jersey, Vereinigte Staaten, 07601
        • John Theurer Cancer Center-Hackensack
    • Ohio
      • Cincinnati, Ohio, Vereinigte Staaten, 45236
        • Oncology Hematology Care Clinical Trials, LLC
      • Columbus, Ohio, Vereinigte Staaten, 43210
        • The Ohio State University Comprehensive Cancer Center
    • Oregon
      • Eugene, Oregon, Vereinigte Staaten, 24224
        • WVCI Oncology Associates of Oregon
      • Portland, Oregon, Vereinigte Staaten, 97239
        • Oregon Health and Science University
    • Pennsylvania
      • Philadelphia, Pennsylvania, Vereinigte Staaten, 19111
        • Temple Health Fox Chase Cancer Center
    • Tennessee
      • Nashville, Tennessee, Vereinigte Staaten, 37203
        • SCRI -TriStar BMT
    • Texas
      • Houston, Texas, Vereinigte Staaten, 77030
        • MD Anderson Cancer Center
    • Virginia
      • Fairfax, Virginia, Vereinigte Staaten, 22031
        • Virginia Cancer Specialists
    • Washington
      • Seattle, Washington, Vereinigte Staaten, 98109
        • Fred Hutchinson Cancer Center

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Signed the informed consent
  2. Age ≥18 years
  3. Has a life expectancy of ≥3 months
  4. Relapsed and/or refractory CD33-positive AML as determined by local pathology review that has failed initial standard of care therapy. Diagnosis of primary AML or AML secondary to myelodysplastic syndromes. Relapsed or refractory status. CD33-positive as confirmed by local flow cytometry or cytology
  5. Has an Eastern Cooperative Oncology Group performance status (ECOG PS) 0 to 2
  6. Toxicity of previous anticancer therapy has returned to Grade ≤1 as defined by NCI CTCAE V5.0, except for alopecia and endocrinopathies controlled by replacement therapy that must be Grade ≤2
  7. Has adequate liver and renal function before registration, defined as: a. Hepatic function: Total bilirubin (TBIL) ≤1.5×ULN (≤3×ULN for subjects with Gilbert's syndrome), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN b. Renal function: Creatinine clearance ≥50 mL/min (Cockcroft-Gault, Chronic Kidney Disease Epidemiology Collaboration [CKD-Epi], or Modification of Diet in Renal Disease Study [MDRD] equations)
  8. Sexually active fertile subjects and their partners must agree to use highly effective methods of contraception during the course of the study and for 7 months after the last dose of study treatment. An additional contraceptive method, such as a barrier method (eg, condom), is recommended
  9. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at screening and must be nonlactating

Exclusion Criteria:

  1. Subjects with acute promyelocytic leukemia (APL) or chronic myelogenous leukemia in blast crisis (CML)

  2. Chemotherapy, biological therapy, immunotherapy, radical radiotherapy, major surgery, targeted therapy (including small molecule inhibitor of tyrosine kinase), and other anticancer therapy within 2 weeks) prior to the first administration; mitomycin and nitrosoureas treatment within 6 weeks prior to the first administration, or palliative radiotherapy within 2 weeks prior to the first administration

  3. Subjects with history of severe heart disease, such as symptomatic congestive heart failure (CHF) ≥ Grade 2 (CTCAE 5.0), New York Heart Association (NYHA) ≥ Grade 2 heart failure, history of transmural myocardial infarction, unstable cardiac arrhythmias or angina pectoris within 6 months before screening

  4. Subjects with prolonged QT interval (QTcF >470 msec), complete left bundle branch block, Grade 3 atrioventricular block or a history of additional risk factors for Torsades de Pointes (TdP; eg, heart failure as defined in Exclusion Criterion 3, chronic or recurrent hypokalemia that requires medical intervention, congenital long QT syndrome, family history of long QT syndrome) or any current concomitant medication known to prolong the QT/QTc interval or cause TdP

  5. Active autoimmune diseases and inflammatory diseases, such as: systemic lupus erythematosus, psoriasis requiring systemic treatment, rheumatoid arthritis, inflammatory bowel disease and Hashimoto's thyroiditis, etc., except for Type I diabetes, hypothyroidism that can be controlled only by standard of care treatment, and skin diseases that do not require systemic treatment (such as vitiligo, psoriasis)

  6. Subjects with other prior or concurrent malignancies except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or carcinoma in situ after adequate resection, or other malignancy treated with curative intent with as disease-free interval of at least 1 year

  7. Subjects with poorly controlled hypertension or uncontrolled hypertension by two or more antihypertensive drugs (systolic blood pressure >150 mmHg or diastolic blood pressure >100 mmHg)

  8. Subjects with active acute or chronic graft vs. host disease (aGVHD or cGVHD) should be excluded from this study. Subjects with GVHD who are receiving treatment with systemic glucocorticoids >10 mg/day equivalent of prednisone should also be excluded from the study; however, treatment with low-dose glucocorticoids (≤10 mg/day equivalent of prednisone) is permitted

  9. Subjects currently receiving immunosuppressive therapy should be excluded from this study.

  10. Clinical evidence of disseminated intravascular coagulation (DIC). Smoldering low grade DIC is allowed after discussion with the sponsor

  11. Subjects with stroke or transient ischemic attack (TIA) within 6 months before screening

  12. Subjects with a thromboembolic event (eg, deep vein thrombosis [DVT] or pulmonary embolism [PE]) within 6 months before screening except for those who are clinically stable and receiving treatment with adequate anticoagulant therapy for at least 3 weeks before screening

  13. Subjects with active central nervous system (CNS) AML will be excluded. A lumbar puncture does not need to be performed unless there is clinical suspicion of CNS involvement per investigator judgment. Concurrent therapy for CNS prophylaxis or continuation of therapy for controlled CNS AML is allowed with the approval of the sponsor

  14. Subjects with pre-existing ≥Grade 2 peripheral neuropathy

  15. Subjects with advanced/ clinically significant lung diseases, such as poorly controlled COPD and asthma, restrictive lung disease, pulmonary hypertension etc.

  16. Subjects who have a history of noninfectious interstitial lung disease (ILD)/ pneumonitis that required treatment with steroids, have current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening

  17. Subjects who have a history of anaphylaxis or severe hypersensitivity to recombinant humanized antibodies or human-mouse chimeric antibodies or any of the components of BL-M11D1

  18. Subjects with known human immunodeficiency virus infection (HIV Ab positive) Subjects are allowed to participate if all of the following criteria are met: (1) Undetectable HIV RNA and CD4 count ≥350 cells/μL at screening, (2) No AIDS defining opportunistic infection within 12 months prior to screening, (3) On stable antiretroviral therapy (ART) for at least 4 weeks prior to screening with projected continuation of ART as clinically indicated while on the study

  19. Subjects with active Hepatitis B virus (HBV) infection (positive HBsAg test). Subjects with chronic inactive HBV infection are eligible if they meet all of the following criteria:

    1. Have a HBV DNA viral load ≤ 500 IU/mL
    2. Have normal AST and ALT, OR if liver involvement is present, has AST and ALT <3 × ULN which are not attributed to HBV infection
    3. on antiviral treatment, as clinically indicated
  20. Subjects with active Hepatitis C virus (HCV) infection (HCV antibody positive and HCV-RNA > the lower limit of detection). Subjects with a positive anti-HCV antibody are eligible only if PCR is negative for HCV RNA

  21. Subjects with active or latent tuberculosis

  22. Subjects with active and uncontrolled infections requiring IV antibiotic, antiviral, or antifungal treatment, such as severe pneumonia, bacteremia, sepsis, etc., within 1 week prior to first dose of study treatment. Subjects on stable oral antimicrobials with no clinical or laboratory evidence of active infection are eligible

  23. Received an investigational drug within 2 weeks prior to first dose of study treatment.

  24. Subjects who are pregnant, breastfeeding, or planning to become pregnant during the study

  25. Prior treatment with a topoisomerase inhibitor-based antibody-drug conjugate (ADC.)

  26. Previous history of significant gastrointestinal conditions, including Grade 3 or higher diarrhea, colitis, gastrointestinal bleeding and history of major gastrointestinal surgeries

28. Progressed on more than 2 different lines of systemic cytotoxic therapies; patients with 3 prior lines of systemic cytotoxic therapy or with prior allogeneic stem cell transplant may be enrolled upon consultation and approval from the sponsor

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Nicht randomisiert
  • Interventionsmodell: Sequenzielle Zuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Experimental: Cohort A BL-M11D1 administered Days 1, 8 and 15 in 28-day cycle

Cohort A: BL-M11D1 will be administered on Days 1, 8 and 15 by intravenous infusion every 28 days.

The study includes 2 parts:

Part 1 Dose escalation and Dose Finding

Experimental: Experimental: Cohort B BL-M11D1 administered Days 1, 4 7 or 8 in 28-day cycle

Cohort B: BL-M11D1 will be administered on Days 1,4, 7 or 8 by intravenous infusion every 28 days.

The study includes 2 parts:

Part 1 Dose escalation and Dose Finding

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Participants with dose-limiting toxicities
Zeitfenster: 1 Year

DLTs are defined as any of the following events that are not clearly due to the underlying disease, disease progression, or extraneous causes:

  • Any treatment-emergent adverse event (TEAE) of ≥ Grade 3 except those due to disease progression or extraneous cause
  • Any TEAE that leads to dose reduction or withdrawal Nonhematologic toxicities
  • Death
  • Hy's law cases
  • Grade ≥3 nonhematologic toxicities (with exceptions) Hematologic toxicity
  • Grade 4 thrombocytopenia or neutropenia lasting >42 days in the absence of persistent leukemia
  • Grade ≥3 platelet count decreased with clinically significant hemorrhage
1 Year
Participants with Serious Adverse Events (SAEs) and treatment-emergent adverse events (TEAEs)
Zeitfenster: 1 Year

Measuring the number of patients with serious adverse events (SAEs) and treatment-emergent adverse events (TEAEs)

1 Year
To determine the minimum safe and effective dose (MSED), maximum tolerated dose (MTD) if reached, and maximum administered dose (MAD) of BL-M11D1 in AML
Zeitfenster: 1 Year

Determine the highest BL-M11D1 dose level at which ≤33% subjects experience a DLT during the DLT evaluation period and highest BL-M11D1 dose administered in the event and MTD cannot be defined.

1 Year

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Cmax of BL-M11D1
Zeitfenster: 1 Year

Calculate maximum (peak) observed concentration of BL-M11D1

1 Year
Tmax of BL-M11D1
Zeitfenster: 1 Year

Calculate time of maximum observed concentration of BL-M1D1

1 Year
Tmax of free payload ED-04
Zeitfenster: 1 Year

Calculate time of maximum observed concentration of free payload ED-04

1 Year
Cmax of free payload ED-04
Zeitfenster: 1 Year

Calculate maximum (peak) observed concentration of free payload ED-04

1 Year
AUC(0-8) of BL-M11D1
Zeitfenster: 1 Year

Calculate area under the serum concentration-time curve of BL-M11D1 from time 0 to 8 hours

1 Year
AUC(0-8) of free payload ED-04
Zeitfenster: 1 Year

Calculate area under the serum concentration-time curve of free payload ED-04 from time 0 to 8 hours

1 Year
AUC(last) of BL-BM11D1
Zeitfenster: 1 Year

Calculate area under the serum concentration-time curve up of BL-M11D1 to the last quantifiable time

1 Year
AUC(last) of free payload ED-04
Zeitfenster: 1 Year

Calculate area under the serum concentration-time curve up of free payload ED-04 to the last quantifiable time

1 Year
Tmax of anti-CD33 antibody
Zeitfenster: 1 Year

Calculate time of maximum observed concentration of anti-CD33 antibody

1 Year
AUC (0-8) of anti-CD33 antibodies
Zeitfenster: 1 Year

Calculate area under the serum concentration-time curve of anti-CD33 antibodies from time 0 to 8 hours

1 Year
AUC (last) anti-CD33 antibodies
Zeitfenster: 1 Year

Calculate area under the serum concentration-time curve up of anti-CD33 antibodies to the last quantifiable time

1 Year
Overall Response Rate (ORR)
Zeitfenster: 1 Year

To assess the clinical efficacy of BL-M11D1 as measured by ORR using RECIST criteria v 1.1

1 Year
Duration of response (DOR)
Zeitfenster: 1 Year

To access the clinical efficacy of BL-M11D1 as measured by DOR using RECIST criteria 1.1

1 Year
Complete Remission (CR)
Zeitfenster: 1 Year

To assess the anti-cancer activity of BL-M11D1 as measured by CR using the European LeukemiaNet (ELN) 2022 AML criteria.

1 Year
CR with partial hematologic recovery (CRh)
Zeitfenster: 1 Year

To assess the anti-cancer activity of BL-M11D1 as measured by CR using the European LeukemiaNet (ELN) 2022 AML criteria.

1 Year
CR with incomplete hematologic recovery (CRi)
Zeitfenster: 1 Year

To assess the anti-cancer activity of BL-M11D1 as measured by CR using the European LeukemiaNet (ELN) 2022 AML criteria.

1 Year
CR/CRi, CRs with or without measurable residual disease (MRD)
Zeitfenster: 1 Year

To assess the anti-cancer activity of BL-M11D1 as measured by CR using the European LeukemiaNet (ELN) 2022 AML criteria.

1 Year
morphologic leukemia-free state (MLFS)
Zeitfenster: 1 Year

To assess the anti-cancer activity of BL-M11D1 as measured by CR using the European LeukemiaNet (ELN) 2022 AML criteria.

1 Year
partial remission (PR)
Zeitfenster: 1 Year

To assess the anti-cancer activity of BL-M11D1 as measured by CR using the European LeukemiaNet (ELN) 2022 AML criteria.

1 Year

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Studienleiter: Olu Lawson, SystImmune Inc.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

19. Dezember 2024

Primärer Abschluss (Tatsächlich)

16. September 2026

Studienabschluss (Tatsächlich)

16. September 2026

Studienanmeldedaten

Zuerst eingereicht

27. November 2024

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

27. November 2024

Zuerst gepostet (Tatsächlich)

3. Dezember 2024

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

24. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

21. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren